Skip to main content
SpringerLink
Log in

VASCULITIS

GCA management guidelines — vive la différence?

  • News & Views
  • Published:

From Nature Reviews Rheumatology

View current issue Sign up to alerts

The ACR have published their first guideline for the management of large vessel vasculitis, which covers giant cell arteritis and Takayasu arteritis. The new guideline differs from the current EULAR recommendations on some important points, but do these different views actually affect patient care?

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Maz, M. et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis. Arthritis Rheumatol. 73, 1349–1365 (2021).

    Article  Google Scholar 

  2. Hellmich, B. et al. 2018 update of the EULAR recommendations for the management of large vessel vasculitis. Ann. Rheum. Dis. 79, 19–30 (2020).

    Article  Google Scholar 

  3. Dejaco, C. et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann. Rheum. Dis. 77, 636–643 (2018).

    Article  Google Scholar 

  4. Monti, S. et al. Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis. RMD Open 5, e001003 (2019).

    Article  Google Scholar 

  5. Duftner, C. et al. Imaging in diagnosis, outcome prediction and monitoring of large vessel vasculitis: a systematic literature review and meta-analysis informing the EULAR recommendations. RMD Open 4, e000612 (2018).

    Article  Google Scholar 

  6. Dua, A. B. et al. Giant cell arteritis: a systematic review and meta-analysis of test accuracy and benefits and harms of common treatments. ACR Open Rheumatol. 3, 429–441 (2021).

    Article  Google Scholar 

  7. Yates, M. et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann. Rheum. Dis. 75, 1583–1594 (2016).

    Article  CAS  Google Scholar 

  8. Labarca, C. et al. Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study. Rheumatology 55, 347–356 (2016).

    Article  Google Scholar 

  9. Stone, J. H. et al. Trial of tocilizumab in giant-cell arteritis. N. Engl. J. Med. 377, 317–328 (2017).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin Rheumatologie und Immunologie, Medius Kliniken, Universität Tübingen, Kirchheim-Teck, Germany

    Bernhard Hellmich

  2. Medizinische Klinik m. S. Rheumatologie und Klinische Immunologie, Charité Universitätsmedizin Berlin (CCM), Berlin, Germany

    Frank Buttgereit

Authors
  1. Bernhard Hellmich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frank Buttgereit
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bernhard Hellmich.

Ethics declarations

Competing interests

B.H. declares receiving speaker fees and/or consultancy fees from Abbvie, AstraZeneca, Chugai, Novartis and Roche, and was convenor of the 2018 EULAR recommendations and the 2020 Deutsche Gesellschaft für Rheumatologie guideline for the management of large vessel vasculitis. F.B. declares receiving consultancy fees, honoraria and travel expenses from Galapagos, Horizon Therapeutics, Roche and Sanofi, and grant support from Horizon Therapeutics, Mundipharma, Roche and Sanofi. He has served as co-principal investigator and site investigator in a Mundipharma sponsored trial in polymyalgia rheumatica, and as principal investigator and site investigator in giant cell arteritis and polymyalgia rheumatica trials sponsored by Sanofi.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hellmich, B., Buttgereit, F. GCA management guidelines — vive la différence?. Nat Rev Rheumatol 17, 649–650 (2021). https://doi.org/10.1038/s41584-021-00686-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41584-021-00686-z

  • Springer Nature Limited

This article is cited by

Search

Navigation